A Guide for Successful Cell and Gene Therapy Research
As researchers continue to expand their understanding and potential uses of innovative cell and gene therapies, it’s critically important for all stakeholders to understand how cell and gene therapy differs from traditional drug development.
The steps and processes involved in research, development, and manufacturing, as well as trial execution, may sometimes overwhelm emerging biopharmaceutical organizations already challenged by limited resources. Cell and gene therapy trials may involve additional safety oversight, special infrastructure for product handling, unique patient and participant relationships, and more.
In this webinar, Sharon Ayd, Vice President and Principal, Regulatory Center of Excellence and Daniel Eisenman, Executive Director of Biosafety Services have a thoughtful discussion of the requirements and considerations involved in cell and gene therapy research.
Learning Objectives:
- Identify current regulatory and clinical challenges for cell and gene therapy
- Describe regulatory and manufacturing challenges unique to cell and gene therapy research
- Define biosafety issues associated with conducting cell and gene therapy research
- Outline the broad range of complexity and risks associated with the use of cell and gene therapy in patients
Presented By
Sharon Ayd
Ph.D, MBA
Vice President & Principal
Advarra Consulting
Daniel Eisenman
PhD, RBP, SM(NRCM), CBSP
Executive Director, Biosafety Services
Advarra
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
DATE: June 17, 2021
Time: 1 pm ET | 10 am PT
Duration: 1 hour